Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn

Open Access
Publisher Website
Google Scholar
Abstract
The cloning of blood group genes and subsequent identification of the molecular bases of blood group polymorphisms has made it possible to predict blood group phenotypes from DNA with a reasonable degree of accuracy. The major application of this technology, which has now become the standard of care, is the determination of a fetal RHD genotype in women with anti‐D, to assess whether the fetus is at risk of haemolytic disease of the fetus and newborn (HDFN). Initially, the procurement of fetal DNA required the invasive procedures of amniocentesis or chorionic villus sampling. Since the discovery of fetal DNA in maternal plasma in 1997, the technology of detecting an RHD gene in this very small quantity of fetal DNA has developed rapidly, so that non‐invasive fetal D typing can now be provided as a diagnostic service for D‐negative pregnant women with anti‐D. Within a few years, it is probable that fetuses of all D‐negative pregnant women will be tested for RHD, to establish whether the mother requires antenatal anti‐D immunoglobulin prophylaxis.